1. Home
  2. CMBM vs LEXX Comparison

CMBM vs LEXX Comparison

Compare CMBM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cambium Networks Corporation

CMBM

Cambium Networks Corporation

HOLD

Current Price

$1.76

Market Cap

33.6M

Sector

Technology

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.72

Market Cap

16.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMBM
LEXX
Founded
2011
2004
Country
United States
Canada
Employees
N/A
7
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.6M
16.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CMBM
LEXX
Price
$1.76
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
131.9K
133.9K
Earning Date
02-19-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$220,195,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.01
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.46
52 Week High
$6.80
$1.90

Technical Indicators

Market Signals
Indicator
CMBM
LEXX
Relative Strength Index (RSI) 73.54 49.84
Support Level $1.34 $0.62
Resistance Level $1.81 $0.87
Average True Range (ATR) 0.14 0.08
MACD 0.06 0.00
Stochastic Oscillator 82.47 32.68

Price Performance

Historical Comparison
CMBM
LEXX

About CMBM Cambium Networks Corporation

Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: